K

    Kiniksa Pharmaceuticals Ltd (KNSA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $78.63
    +0.55 (+0.70%)

    Market Cap: $6.05B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    52%(17/33)
    Avg Surprise
    -31.08%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.32
    Range$0.28 - $0.37
    4 analysts
    EPS RevisionsNo revisions (7d)
    2
    2
    30d
    EPS Estimate Drift
    90d ago$0.32+2.4%
    60d ago$0.32+2.4%
    30d ago$0.32+2.4%
    7d ago$0.32+0.0%
    Current$0.32
    Revenue Consensus
    $260M
    Range$258M - $263M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.40
    Range$0.31 - $0.47
    4 analysts
    Revenue Consensus
    $302M
    Range$298M - $306M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.40---
    Sep 26EST
    		-$0.32---
    Jun 26
    Reported Jul 28
    		$0.30$0.30+0.00%Beat+30.4%
    Mar 26
    Reported Apr 28
    		$0.27$0.16+68.75%Beat+145.5%
    Dec 25
    Reported Feb 24
    		$0.17N/A-57.50%Miss+241.7%
    Sep 25
    Reported Oct 28
    		$0.23$0.37-37.84%Miss+227.8%
    Jun 25
    Reported Jul 29
    		$0.23$0.26-11.54%Miss+483.3%
    Mar 25
    Reported Apr 29
    		$0.11N/A-60.71%Miss+144.0%
    Dec 24
    Reported Feb 25
    		$-0.12$0.02-700.00%Miss-134.3%
    Sep 24
    Reported Oct 29
    		$-0.18$0.07-357.14%Miss+10.0%
    Jun 24
    Reported Jul 23
    		$-0.06$0.01-700.00%Miss-128.6%
    Mar 24
    Reported Apr 23
    		$-0.25$-0.08-212.50%Miss-38.9%
    Dec 23
    Reported Feb 28
    		$0.35$-0.14+350.00%Beat+483.3%
    Sep 23
    Reported Oct 31
    		$-0.20$-0.16-25.00%Miss-106.3%
    Jun 23
    Reported Jul 25
    		$0.21$-0.13+261.54%Beat+172.4%
    Mar 23
    Reported May 2
    		$-0.18$-0.21+14.29%Beat+50.0%
    Dec 22
    Reported Feb 28
    		$0.06N/A+142.86%Beat+111.3%
    Sep 22
    Reported Nov 1
    		$3.18$0.83+283.13%Beat+822.7%
    Jun 22
    Reported Aug 3
    		$-0.29$-0.39+25.64%Beat+52.5%
    Mar 22
    Reported May 3
    		$-0.36$-0.26-38.46%Miss+50.0%
    Dec 21
    Reported Feb 22
    		$-0.53$-0.42-26.19%Miss+32.9%
    Sep 21
    Reported Nov 1
    		$-0.44$-0.63+30.16%Beat+33.3%
    Jun 21
    Reported Aug 3
    		$-0.61$-0.77+20.78%Beat+6.2%
    Mar 21
    Reported May 4
    		$-0.72$-0.63-14.29%Miss-50.0%
    Dec 20
    Reported Feb 23
    		$-0.79$-0.62-27.42%Miss-36.2%
    Sep 20
    Reported Nov 5
    		$-0.66$-0.59-11.86%Miss-34.7%
    Jun 20
    Reported Jul 30
    		$-0.65$-0.58-12.07%Miss+4.4%
    Mar 20
    Reported Apr 28
    		$-0.48$-0.62+22.58%Beat+34.2%
    Dec 19
    Reported Feb 26
    		$-0.58$-0.62+6.45%Beat+34.1%
    Sep 19
    Reported Oct 28
    		$-0.49$-0.70+30.00%Beat+3.9%
    Jun 19
    Reported Aug 12
    		$-0.68$-0.76+10.53%Beat-44.7%
    Mar 19
    Reported May 2
    		$-0.73$-0.79+7.59%Beat-630.0%
    Dec 18
    Reported Mar 7
    		$-0.88$-0.75-17.33%Miss-4500.0%
    Sep 18
    Reported Nov 1
    		$-0.51$-0.53+3.77%Beat-
    Jun 18
    Reported Aug 6
    		$-0.47$-0.50+6.00%Beat-
    Mar 18
    Reported May 24
    		$-0.10N/AN/ABeat-
    Dec 17
    Reported Mar 30
    		$0.02$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio81.06EV/EBITDA55.91x
    Price/FCF33.36xFCF Yield3.00%
    Profitability
    Profit Margin9.59%Operating Margin11.20%
    ROE14.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.90xQuick Ratio3.49x
    Trading Statistics
    Beta0.09Avg Volume447.67K
    52-Week High$82.9452-Week Low$34.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$79.26
    SMA 20$78.27
    SMA 50$70.17
    SMA 200$52.11
    EMA 10$78.75
    EMA 20$77.22
    EMA 50$70.92
    EMA 200$54.67

    MACD

    Line: 2.60Signal: 3.25Hist: -0.65

    ADX

    ADX: 35.3+DI: 23.5-DI: 17.4

    Aroon & PSAR

    Aroon Up8.0
    Aroon DownN/A
    PSAR$82.94

    Bollinger Bands

    Upper Band$81.02
    Lower Band$75.52
    %B Position703%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    58.0

    Momentum Oscillators

    Stoch %K56.9
    Stoch %D61.4
    Williams %R-46.9
    ROC (10d)-0.7%
    Momentum-0.55
    CCI (20d)-8.2
    MFI (14d)58.1

    Volatility Measures

    ATR (14d)$2.66(3.4%)
    StdDev (20d)1.38
    Hist Vol28.4%(Moderate)

    Volume Flow

    VWAP$78.03
    OBV26.9M
    AD Line19.5M
    CMF (20d)0.163

    Volume Metrics

    Avg Vol (20d)430.8K
    Vol Ratio1.0x
    VWMA (20d)$78.40

    Pivot Points

    R3$81.46
    R2$80.63
    R1$79.36
    Pivot Point$78.53
    S1$77.26
    S2$76.43
    S3$75.16

    Advanced Oscillators

    TSI24.09
    Ultimate Osc55.8
    KST149.64

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$243.60M$214.27M$202.13M$180.85M$156.80M$137.78M$122.54M$112.21M$108.63M$79.86M$83.39M$67.05M
    Cost of Revenue$111.64M$96.37M$90.97M$83.56M$71.02M$61.66M$66.08M$49.42M$42.34M$31.38M$26.52M$26.40M
    Gross Profit$131.96M$117.89M$111.15M$97.29M$85.78M$76.13M$56.45M$62.80M$66.30M$48.47M$56.87M$40.65M
    Operating Expenses$104.77M$88.63M$91.38M$73.27M$65.62M$62.85M$75.75M$72.46M$66.41M$65.02M$56.79M$51.57M
    R&D$40.90M$27.48M$34.61M$24.17M$18.75M$19.32M$35.22M$26.06M$24.02M$26.33M$20.05M$17.11M
    SG&A$63.87M$61.15M$56.77M$49.10M$46.86M$43.53M$40.53M$46.40M$42.40M$38.68M$36.74M$34.47M
    Operating Income$27.19M$29.27M$19.77M$24.02M$20.16M$13.27M$-19,299,000$-9,658,000$-117,000$-16,542,000$81,000$-10,927,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$31.14M$32.68M$23.27M$27.16M$22.88M$15.56M$-16,979,000$-7,201,000$2.30M$-14,276,000$2.45M$-8,499,000
    Income Tax Expense$5.71M$10.09M$9.07M$8.72M$5.04M$7.03M$-8,091,000$5.49M$6.21M$3.43M$-22,787,000$5.36M
    Net Income$25.43M$22.59M$14.20M$18.43M$17.83M$8.54M$-8,888,000$-12,693,000$-3,908,000$-17,704,000$25.24M$-13,855,000
    EBITDA$31.71M$34.45M$22.81M$28.14M$22.39M$16.16M$-15,760,000$-7,289,000$2.55M$-13,513,000$2.69M$-6,455,000
    EBIT$31.14M$32.68M$23.27M$27.16M$22.88M$15.56M$-16,979,000$-7,201,000$2.30M$-14,276,000$2.45M$-8,499,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KNSA

    Government Contracts

    Gov Obligations (TTM)
    $328283
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    6
    New Awards (TTM)
    5
    Avg Remaining Term
    4.3 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0076Department of Veterans AffairsDepartment of Veterans Affairs$220229Dec 15, 2025
    36C24526N0595Department of Veterans AffairsDepartment of Veterans Affairs$34023May 21, 2026
    36C24526N0418Department of Veterans AffairsDepartment of Veterans Affairs$34023Mar 18, 2026
    36C24526N0294Department of Veterans AffairsDepartment of Veterans Affairs$34023Jan 31, 2026
    36C24526N0196Department of Veterans AffairsDepartment of Veterans Affairs$32187Dec 22, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Headlands Technologies LLC Purchases Shares of 18,161 Kiniksa Pharmaceuticals International, plc $KNSA

    Headlands Technologies LLC acquired 18,161 shares of Kiniksa Pharmaceuticals International, plc, valued at approximately $1.16 million, during the second quarter. The company has a "Moderate Buy" consensus rating from analysts, with an average price target of $87.38. Kiniksa Pharmaceuticals reported strong quarterly revenue and earnings that met estimates, and its stock is currently trading near its 52-week high.

    MarketBeat•9/1/26•
    Somewhat-Bullish

    Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Moderate Buy" by Brokerages

    Kiniksa Pharmaceuticals International (NASDAQ:KNSA) has received an average "Moderate Buy" rating from ten brokerages, with eight analysts recommending a "buy" and two a "hold." The consensus 1-year price target for the stock is $87.3750. Recent analyst reports have seen several price target increases, reflecting a positive outlook on the company's performance, which recently exceeded revenue expectations and saw a significant surge in share price.

    MarketBeat•8/31/26•
    Bullish

    Kiniksa Director Barry D Quart Donates 2,600 Class A Shares to Donor Advised Fund

    Kiniksa Pharmaceuticals International, plc director Barry D Quart donated 2,600 Class A Ordinary Shares to a donor advised fund on August 19, 2026. This gift, valued at $0 per share, was disclosed in a Form 4 filing on August 21, 2026. After the transaction, Quart directly holds 12,745 Class A Ordinary Shares.

    Kalkine Media•8/21/26•
    Neutral

    Kiniksa (NASDAQ: KNSA) director gifts 2,600 shares to donor fund

    Kiniksa Pharmaceuticals International, plc director Barry D. Quart reported a bona fide gift of 2,600 Class A Ordinary Shares to a donor advised fund on August 19, 2026, with a reported transaction price of $0.00 per share. Following this transaction, Quart directly holds 12,745 Class A Ordinary Shares. This transaction is classified as a gift and not a sale under a 10b5-1 trading plan.

    Stock Titan•8/21/26•
    Neutral

    Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N

    Kiniksa Pharmaceuticals International, plc (BIVA:KNSA/N) generated 12.21 billion MXN in revenue last year, primarily from its Therapeutic Medicines segment. The United States was the largest contributor to this revenue, accounting for 12.20 billion MXN. This represents an increase from the previous year's segment revenue of 8.82 billion MXN.

    TradingView•8/15/26•
    Somewhat-Bullish

    Frequently Asked Questions About KNSA

    Does KNSA pay dividends?
    Kiniksa Pharmaceuticals Ltd (KNSA) does not currently pay a regular dividend.
    What is KNSA's P/E ratio?
    Kiniksa Pharmaceuticals Ltd has a price-to-earnings (P/E) ratio of 81.06.
    What is KNSA's market cap?
    Kiniksa Pharmaceuticals Ltd (KNSA) has a market capitalization of $6.05B with a current stock price of $78.63.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In